Wed 09 Jan 2019 AgilVax Elects Dr. David T. Hung, Former Founder and CEO of Medivation, to Its Board of Directors Read More
Tue 07 Aug 2018 AgilVax Awarded $2.3 Million SBIR Fast Track Grant to Advance the Development of AX09 for Triple Negative Breast Cancer Read More
Tue 15 May 2018 AgilVax Closes A1 Financing to Expand Pre-IND Studies for AX09 In Triple Negative Breast Cancer Read More
Thu 04 Jan 2018 AgilVax to Attend J.P. Morgan Healthcare Conference, Biotech Showcase™ 2018 & RESI San Francisco 2018 Read More
Tue 05 Dec 2017 New Scientific Publication Supports AgilVax’s Novel Immunotherapy Development for Metastatic Breast Cancer Read More
